MCID: MLG065
MIFTS: 41

Malignant Fibroxanthoma

Categories: Cancer diseases

Aliases & Classifications for Malignant Fibroxanthoma

MalaCards integrated aliases for Malignant Fibroxanthoma:

Name: Malignant Fibroxanthoma 12 14
Malignant Fibrous Histiocytoma 72 13 51 69
Fibrous Histiocytoma, Malignant 12
Histiocytoma, Malignant Fibrous 41
Fibroxanthosarcoma 12
Mfh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1907
MeSH 41 D051677
NCIt 46 C4247
UMLS 69 C0334463

Summaries for Malignant Fibroxanthoma

MalaCards based summary : Malignant Fibroxanthoma, also known as malignant fibrous histiocytoma, is related to inflammatory mfh and fibrous histiocytoma. An important gene associated with Malignant Fibroxanthoma is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Cytoskeletal Signaling and DNA Damage. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and endothelial, and related phenotypes are homeostasis/metabolism and muscle

Wikipedia : 72 Undifferentiated pleomorphic sarcoma (UPS), also undifferentiated pleomorphic sarcoma (PUS) and... more...

Related Diseases for Malignant Fibroxanthoma

Diseases related to Malignant Fibroxanthoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 inflammatory mfh 33.2 CDK4 MDM2 SERPINA1 SERPINA3
2 fibrous histiocytoma 30.4 ACTC1 DES F13A1 SERPINA3 VIM
3 histiocytoma 28.7 ALK CDK4 MDM2 MYOD1 PTPRC SERPINA3
4 undifferentiated pleomorphic sarcoma 11.3
5 malignant skin fibrous histiocytoma 11.2
6 diaphyseal medullary stenosis with malignant fibrous histiocytoma 10.9
7 nodular tenosynovitis 10.5 PTPRC SERPINA3
8 breast rhabdomyosarcoma 10.5 DES MYOD1
9 ring chromosome 7 10.5 CDK4 MDM2
10 cervical polyp 10.5 DES MYOD1
11 gallbladder sarcoma 10.5 DES MYOD1
12 infiltrating angiolipoma 10.4 CDK4 MDM2
13 conventional fibrosarcoma 10.4 MDM2 PTPRC
14 bone osteosarcoma 10.4 CDK4 MDM2
15 skin glomus tumor 10.4 DES VIM
16 progressive nodular histiocytosis 10.4 ACTC1 F13A1
17 inflammatory leiomyosarcoma 10.4 DES MYOD1
18 infantile digital fibromatosis 10.4 DES VIM
19 lymphangiomatosis 10.4 DES VIM
20 myofibroma 10.4 DES F13A1
21 lipoblastoma 10.4 CDK4 MDM2
22 scleromyxedema 10.4 ACTC1 F13A1
23 horner's syndrome 10.4 DES MYOD1
24 testicular yolk sac tumor 10.4 MDM2 SERPINA1 SERPINA3
25 granuloma annulare 10.3 F13A1 VIM
26 mesenchymoma 10.3 DES MDM2 MYOD1
27 reticulohistiocytic granuloma 10.3 PTPRC SERPINA1 SERPINA3
28 ovarian fibrothecoma 10.3 ACTC1 DES
29 mixed liposarcoma 10.3 CDK4 MDM2
30 epulis 10.3 DES VIM
31 muscle cancer 10.3 DES MDM2 MYOD1
32 spindle cell liposarcoma 10.3 CDK4 MDM2 MYOD1
33 extraosseous osteosarcoma 10.3 CDK4 MDM2 PTPRC
34 lymphangiectasis 10.3 ACTC1 VIM
35 connective tissue cancer 10.3 CDK4 MDM2 SERPINA3
36 glomangiomyoma 10.3 ACTC1 VIM
37 retroperitoneal fibrosis 10.3 MDM2 PTPRC VIM
38 periosteal chondrosarcoma 10.3 CDK4 MDM2
39 cutaneous solitary mastocytoma 10.3 SERPINA1 SERPINA3
40 periosteal osteogenic sarcoma 10.3 CDK4 MDM2
41 generalized eruptive histiocytosis 10.3 F13A1 S100B
42 spindle cell thymoma 10.3 DES MUC1
43 multicentric reticulohistiocytosis 10.3 F13A1 PTPRC VIM
44 lipomatosis, multiple 10.2 CDK4 DES MDM2
45 primitive neuroectodermal tumor of the cervix uteri 10.2 DES PTPRC VIM
46 malignant peritoneal mesothelioma 10.2 MUC1 VIM
47 embryonal rhabdomyosarcoma 10.2 CDK4 DES MYOD1
48 atypical lipomatous tumor 10.2 CDK4 MDM2
49 papillary tumor of the pineal region 10.2 MUC1 VIM
50 malignant mixed mullerian tumor 10.2 MUC1 VIM

Graphical network of the top 20 diseases related to Malignant Fibroxanthoma:



Diseases related to Malignant Fibroxanthoma

Symptoms & Phenotypes for Malignant Fibroxanthoma

MGI Mouse Phenotypes related to Malignant Fibroxanthoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.85 ACTC1 ALK CDK4 DES F13A1 MDM2
2 muscle MP:0005369 9.43 ACTC1 CDK4 DES MDM2 MYOD1 VIM
3 normal MP:0002873 9.17 ACTC1 CDK4 MDM2 MKI67 MYOD1 PTPRC

Drugs & Therapeutics for Malignant Fibroxanthoma

Drugs for Malignant Fibroxanthoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
7
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Lenograstim Approved, Investigational Phase 3 135968-09-1
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
15
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Antiviral Agents Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
25 Antirheumatic Agents Phase 3,Phase 2,Phase 1
26 Etoposide phosphate Phase 3,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
29 Antimetabolites Phase 3,Phase 1,Phase 2
30 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
31
Indinavir Approved Phase 2 150378-17-9 5362440
32
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
37
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
38
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 6436030 5284616
40
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
41
nivolumab Approved Phase 2,Phase 1 946414-94-4
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
44
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
48
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
49
Saracatinib Investigational Phase 2 379231-04-6
50 Soblidotin Investigational Phase 2 149606-27-9

Interventional clinical trials:

(show top 50) (show all 62)

# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
14 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
16 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
20 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
23 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
24 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
25 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
26 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
27 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
28 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
29 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
30 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
31 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
32 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
36 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
37 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
38 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
39 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
40 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
41 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
42 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
43 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
44 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
45 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03414229 Phase 2 Epacadostat;Pembrolizumab
46 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
47 Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Not yet recruiting NCT03474094 Phase 2
48 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
49 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
50 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2

Search NIH Clinical Center for Malignant Fibroxanthoma

Cochrane evidence based reviews: histiocytoma, malignant fibrous

Genetic Tests for Malignant Fibroxanthoma

Anatomical Context for Malignant Fibroxanthoma

MalaCards organs/tissues related to Malignant Fibroxanthoma:

38
Bone, Lung, Endothelial, Testes, Liver, Brain

Publications for Malignant Fibroxanthoma

Articles related to Malignant Fibroxanthoma:

# Title Authors Year
1
Malignant fibroxanthoma: a sarcoma of the vulva. ( 4704007 )
1973
2
Fibrosarcoma (malignant fibroxanthoma) involving conjunctiva and ciliary body. ( 5053693 )
1972
3
Ultrastructure of a fibroxanthosarcoma (malignant fibroxanthoma). ( 4105302 )
1971
4
Metastasizing retroperitoneal fibroxanthoma (malignant fibroxanthoma). ( 5506607 )
1970
5
Malignant fibroxanthoma (malignant histiocytoma): an ill-defined histologic entity with unpredictable biologic behavior. Report of a case with long-term survival. ( 4248417 )
1970

Variations for Malignant Fibroxanthoma

Copy number variations for Malignant Fibroxanthoma from CNVD:

7 (show all 41)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18958 1 148000000 153300000 Gain Malignant fibrous histiocytomas
2 27753 1 212100000 222100000 Loss Malignant fibrous histiocytomas
3 33593 1 46500000 56200000 Gain Malignant fibrous histiocytomas
4 35188 1 60900000 69500000 Gain Malignant fibrous histiocytomas
5 37769 1 94500000 99400000 Gain Malignant fibrous histiocytomas
6 39415 10 114900000 121700000 Loss Malignant fibrous histiocytomas
7 50207 11 115400000 134452384 Loss Malignant fibrous histiocytomas
8 59633 11 76700000 85300000 Loss Malignant fibrous histiocytomas
9 60562 11 87900000 96700000 Loss Malignant fibrous histiocytomas
10 69083 12 5300000 14800000 Gain Malignant fibrous histiocytomas
11 76673 13 34700000 48900000 Loss Malignant fibrous histiocytomas
12 78011 13 48900000 57600000 Loss Malignant fibrous histiocytomas
13 86677 14 64000000 88900000 Gain Malignant fibrous histiocytomas
14 88587 14 92800000 106368585 Gain Malignant fibrous histiocytomas
15 101715 16 45500000 54500000 Loss Malignant fibrous histiocytomas
16 103579 16 6300000 10300000 Loss Malignant fibrous histiocytomas
17 107007 17 11200000 15900000 Gain Malignant fibrous histiocytomas
18 107027 17 11200000 22100000 Gain Malignant fibrous histiocytomas
19 107535 17 15900000 22100000 Gain Malignant fibrous histiocytomas
20 112060 17 37800000 44800000 Gain Malignant fibrous histiocytomas
21 119810 18 17300000 23300000 Gain Malignant fibrous histiocytomas
22 122735 18 59800000 76117153 Loss Malignant fibrous histiocytomas
23 127802 19 37100000 47800000 Gain Malignant fibrous histiocytomas
24 134297 2 1 12800000 Loss Malignant fibrous histiocytomas
25 142547 2 225800000 237000000 Loss Malignant fibrous histiocytomas
26 154853 20 49200000 54400000 Gain Malignant fibrous histiocytomas
27 163375 22 27900000 35900000 Gain Malignant fibrous histiocytomas
28 163745 22 30500000 39300000 Gain Malignant fibrous histiocytomas
29 164763 22 39300000 49691432 Loss Malignant fibrous histiocytomas
30 178974 3 83700000 89400000 Gain Malignant fibrous histiocytomas
31 187572 4 52400000 59200000 Gain Malignant fibrous histiocytomas
32 192956 5 121500000 143100000 Loss Malignant fibrous histiocytomas
33 198017 5 18500000 23300000 Gain Malignant fibrous histiocytomas
34 214607 6 63500000 75900000 Gain Malignant fibrous histiocytomas
35 221899 7 147500000 158821424 Loss Malignant fibrous histiocytomas
36 225328 7 4500000 7200000 Gain Malignant fibrous histiocytomas
37 226671 7 61100000 71800000 Gain Malignant fibrous histiocytomas
38 237234 8 2200000 19100000 Loss Malignant fibrous histiocytomas
39 244141 8 93500000 99100000 Gain Malignant fibrous histiocytomas
40 250775 9 2200000 9000000 Loss Malignant fibrous histiocytomas
41 255895 9 86100000 113900000 Gain Malignant fibrous histiocytomas

Expression for Malignant Fibroxanthoma

Search GEO for disease gene expression data for Malignant Fibroxanthoma.

Pathways for Malignant Fibroxanthoma

Pathways related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.05 ACTC1 DES MUC1 VIM
2 11.73 CDK4 MDM2 MKI67 VIM
3 11.55 F13A1 MUC1 VIM
4 11.31 DES MYOD1 PTPRC
5 10.66 ACTC1 DES VIM

GO Terms for Malignant Fibroxanthoma

Cellular components related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.56 ACTC1 ALK DES MUC1 PTPRC SERPINA1
2 platelet alpha granule lumen GO:0031093 8.8 F13A1 SERPINA1 SERPINA3

Biological processes related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.33 F13A1 SERPINA1 SERPINA3
2 negative regulation of cell cycle arrest GO:0071157 9.26 CDK4 MDM2
3 intermediate filament organization GO:0045109 8.96 DES VIM
4 muscle filament sliding GO:0030049 8.8 ACTC1 DES VIM

Molecular functions related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.1 ALK DES MDM2 S100B SERPINA1 VIM

Sources for Malignant Fibroxanthoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....